Application and development of TCR-T in tumor therapy

As cancer has gradually become the world's deadliest long-term disease, the impact on the public health has been devastating. Especially the Melanoma which is a cancer with a very high malignant and a high fatality rate. With the emergence of adoptive cell therapy(ACT) based on T Cell Receptor-Gene Engineered T Cells (TCR-T), good results have been obtained in scientific research and clinical fields for a variety of malignant tumors. As TCR-T continues to enter the clinic, the FDA also has approved the first case of TCR-T in 2022, and more and more basic researches and clinical trial projects based on TCR-T are gradually being carried out. However, TCR-T therapy still has some defects, such as non-tumor tissue damage caused by off-target effect and insufficient affinity with tumor tissue. Therefore, the affinity and anti-tumor effectiveness of TCR-T should be improved in multiple aspects, and multi-field cooperation should be carried out to promote the development of basic research, a number of products should be introduced into the clinic, and the intervention of economic means to improve the accessibility of TCR-T. Not only brings the Gospel of cure to patients in the field of solid tumors, but also produces innovation in the field of non-solid tumors.